Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02549573 · ClinicalTrials.gov registry record · Phase 4
Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®
A Phase 4 study, sponsored by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT02549573: Clinical Trial Phase 4 study, sponsored by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals.
NCT02549573 is a Phase 4 study that was terminated before completion, run by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals. The registered enrollment target is 13 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02549573, a Phase 4 study, was terminated before completion, sponsored by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
To determine if PT intervention will be improved while in the "on" motor state vs. the "end-of-dose-off" motor state during the PT Intervention Visit in subjects with PD.
Primary Outcome
Scale from 0 to 100% where an increase in percent represents an improvement in balance confidence.
Interventions
- BEHAVIORAL Physical Therapy
- DRUG APOKYN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-12 |
| Phase | Phase 4 |
Why NCT02549573 stopped before completion
NCT02549573 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Physical Therapy is the first listed.
NCT02549573 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02549573 about?
NCT02549573 is a clinical study titled "Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®". To determine if PT intervention will be improved while in the "on" motor state vs. the "end-of-dose-off" motor state during the PT Intervention Visit in subjects with PD.
What is the current status of trial NCT02549573?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2016-01. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02549573?
The interventions under investigation include: Physical Therapy (BEHAVIORAL), APOKYN (DRUG).
Who is sponsoring clinical trial NCT02549573?
This trial is sponsored by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02549573's enrollment target sits among peer trials
13 1910th of 2000 higher than 88 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia